BMI View: Gabon's small pharmaceutical market will continue to act as a deterrent to any local
investments by multinational drugmakers. Opportunities will be largely focused within the generic drug
market, yet over the long term, as the national health insurance schem ..."
BMI View: Gabon's pharmaceutical and healthcare markets will be challenged by insufficient healthcare
infrastructure, the lack of domestic manufacturing capabilities and a weakening oil sector. The country
suffers from a small pharmaceutical market size and low afford ..."
BMI View: Gabon's small pharmaceutical market size will continue to discourage investment from
multinational pharmaceutical companies. Over the long-term, the country's evolving demographic profile,
boosts to domestic manufacturing capabilities, and the success of the ..."
BMI View: Gabon's pharmaceutical market growth will be boosted as coverage of the national health
insurance scheme expands. Opportunities will be focussed within the generic drug market, however, and
Gabon's small market size will continue to act as a deterrent to any ..."
BMI View: This quarter has seen the expansion of the National Health Insurance and Social Security
(CNAMGS) to include the entire private sector, and funding for the scheme has also been increased. This
continued expansion, coupled with a high burden of disease, will ..."
BMI View: Low incomes and limited government budgets in emerging markets generally preclude the
uptake of modern medicines for diseases such as cancer, despite strong underlying demand from patients
and prescribers. As economies in non-traditional markets such as Gabo ..."
BMI View: Oil production in the country is stagnating. Despite government efforts to increase revenues
from the mining sector, BMI predicts that a combination of faltering production and relatively subdued oil
prices will prevent government revenues from rising in the face of b ..."
BMI View: While geographic diversification and investment into the pharmaceutical and healthcare
sectors of emerging economies like Gabon may be a favourable strategy for any multinational
pharmaceutical company, it is vital that a company recognises both the rewards and the ri ..."
BMI View: Increased longevity in developed markets translates into an increased demand for care for the elderly, healthcare services and medicines. However, despite increased life expectancy, in emerging markets such as Gabon communicable diseases will remain a significant health ..."
BMI View: There are emerging downside risks to our Gabon pharmaceutical and healthcare expenditure forecasts. Economic expansion is stagnating, which could lead to political instability. The country's muchpraised universal healthcare system is undergoing reforms, and the infectio ..."